| Year |
Citation |
Score |
| 2014 |
Klos KS, Warmka JK, Drachenberg DM, Chang L, Luxton GW, Leung CT, Schwertfeger KL, Wattenberg EV. Building bridges toward invasion: tumor promoter treatment induces a novel protein kinase C-dependent phenotype in MCF10A mammary cell acini. Plos One. 9: e90722. PMID 24599099 DOI: 10.1371/Journal.Pone.0090722 |
0.366 |
|
| 2013 |
Liu Z, Liu H, Desai S, Schmitt DC, Zhou M, Khong HT, Klos KS, McClellan S, Fodstad O, Tan M. miR-125b functions as a key mediator for snail-induced stem cell propagation and chemoresistance. The Journal of Biological Chemistry. 288: 4334-45. PMID 23255607 DOI: 10.1074/Jbc.M112.419168 |
0.394 |
|
| 2006 |
Klos KS, Wyszomierski SL, Sun M, Tan M, Zhou X, Li P, Yang W, Yin G, Hittelman WN, Yu D. ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Research. 66: 2028-37. PMID 16489002 DOI: 10.1158/0008-5472.Can-04-4559 |
0.741 |
|
| 2005 |
Tan M, Li P, Klos KS, Lu J, Lan KH, Nagata Y, Fang D, Jing T, Yu D. ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis. Cancer Research. 65: 1858-67. PMID 15753384 DOI: 10.1158/0008-5472.Can-04-2353 |
0.706 |
|
| 2004 |
Zhou X, Tan M, Stone Hawthorne V, Klos KS, Lan KH, Yang Y, Yang W, Smith TL, Shi D, Yu D. Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 6779-88. PMID 15501954 DOI: 10.1158/1078-0432.Ccr-04-0112 |
0.791 |
|
| 2004 |
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, Hortobagyi GN, Hung MC, Yu D. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 6: 117-27. PMID 15324695 DOI: 10.1016/J.Ccr.2004.06.022 |
0.758 |
|
| 2004 |
Klos KS, Yu D. Liposomal mediated transfer of ErbB2 antisense DNA: coming of age in the war against cancer. Cancer Biology & Therapy. 3: 205-6. PMID 14764991 DOI: 10.4161/Cbt.3.2.714 |
0.635 |
|
| 2003 |
Klos KS, Zhou X, Lee S, Zhang L, Yang W, Nagata Y, Yu D. Combined trastuzumab and paclitaxel treatment better inhibits ErbB-2-mediated angiogenesis in breast carcinoma through a more effective inhibition of Akt than either treatment alone. Cancer. 98: 1377-85. PMID 14508823 DOI: 10.1002/cncr.11656 |
0.617 |
|
| 2003 |
Yang W, Klos KS, Zhou X, Yao J, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression in human breast carcinoma is correlated with p21Cip1 up-regulation and tyrosine-15 hyperphosphorylation of p34Cdc2: poor responsiveness to chemotherapy with cyclophoshamide methotrexate, and 5-fluorouracil is associated with Erb2 overexpression and with p21Cip1 overexpression. Cancer. 98: 1123-30. PMID 12973835 DOI: 10.1002/Cncr.11625 |
0.7 |
|
| 2002 |
Lee S, Yang W, Lan KH, Sellappan S, Klos K, Hortobagyi G, Hung MC, Yu D. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells. Cancer Research. 62: 5703-10. PMID 12384528 |
0.69 |
|
| 2002 |
Yang W, Klos K, Yang Y, Smith TL, Shi D, Yu D. ErbB2 overexpression correlates with increased expression of vascular endothelial growth factors A, C, and D in human breast carcinoma. Cancer. 94: 2855-61. PMID 12115372 DOI: 10.1002/cncr.10553 |
0.572 |
|
| 2001 |
Yao J, Xiong S, Klos K, Nguyen N, Grijalva R, Li P, Yu D. Multiple signaling pathways involved in activation of matrix metalloproteinase-9 (MMP-9) by heregulin-beta1 in human breast cancer cells. Oncogene. 20: 8066-74. PMID 11781819 DOI: 10.1038/Sj.Onc.1204944 |
0.714 |
|
| Show low-probability matches. |